$ABTI
ALTEROLA BIOTECH INC.

2024 Q4 Form 10-Q Financial Statement

#000147793224007731 Filed on November 29, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2024 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $256.8K
YoY Change -157.06%
% of Gross Profit
Research & Development $16.96K $25.89K
YoY Change -91.91%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $477.2K $282.7K
YoY Change 287.5% 303.79%
Operating Profit -$477.2K
YoY Change 287.5%
Interest Expense $337.3K $27.65K
YoY Change
% of Operating Profit
Other Income/Expense, Net -$322.0K $194.8K
YoY Change 161.43%
Pretax Income $490.8K
YoY Change -801.19%
Income Tax $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings -$799.2K $490.8K
YoY Change 548.93% -2554.15%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.00
COMMON SHARES
Basic Shares Outstanding 1.460B shares 1.460B shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q4 2024 Q3 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.650K
YoY Change -73.5%
Cash & Equivalents $82.72K $2.654K
Short-Term Investments
Other Short-Term Assets $0.00
YoY Change -100.0%
Inventory $1.069K $1.009K
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $1.147M $3.663K
YoY Change 481.63% -98.46%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $217.0K $0.00
YoY Change -27.65% -100.0%
TOTAL ASSETS
Total Short-Term Assets $1.147M $3.663K
Total Long-Term Assets $217.0K $0.00
Total Assets $1.364M $3.663K
YoY Change 174.35% -99.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $805.3K $825.2K
YoY Change 11.52% 34.88%
Accrued Expenses $462.0K $362.5K
YoY Change 87.52% 42.21%
Deferred Revenue
YoY Change
Short-Term Debt $145.6K
YoY Change -88.44%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.615M $1.333M
YoY Change 43.51% -37.32%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change -100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.615M $1.333M
Total Long-Term Liabilities $0.00
Total Liabilities $3.615M $1.333M
YoY Change 43.51% -41.56%
SHAREHOLDERS EQUITY
Retained Earnings -$13.67M -$12.42M
YoY Change 31.09% 29.65%
Common Stock $1.467M $1.383M
YoY Change 88.61% 71.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.055M -$1.330M
YoY Change
Total Liabilities & Shareholders Equity $1.364M $3.663K
YoY Change 174.35% -99.97%

Cashflow Statement

Concept 2024 Q4 2024 Q3 2024 Q1
OPERATING ACTIVITIES
Net Income -$799.2K $490.8K
YoY Change 548.93% -2554.15%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$73.59K
YoY Change -149.06%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 179.3K
YoY Change 49.42%
NET CHANGE
Cash From Operating Activities -73.59K
Cash From Investing Activities
Cash From Financing Activities 179.3K
Net Change In Cash 105.7K
YoY Change -3.9%
FREE CASH FLOW
Cash From Operating Activities -$73.59K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Address Country
EntityAddressCountry
GB
dei City Area Code
CityAreaCode
151
dei Local Phone Number
LocalPhoneNumber
601 9477
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1459502018 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
82720 usd
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2654 usd
CY2024Q3 abti Loans Receivable Current Amount
LoansReceivableCurrentAmount
1063235 usd
CY2024Q1 abti Loans Receivable Current Amount
LoansReceivableCurrentAmount
0 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
1069 usd
CY2024Q1 us-gaap Inventory Net
InventoryNet
1009 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
1147024 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
3663 usd
CY2024Q3 us-gaap Intangible Assets Current
IntangibleAssetsCurrent
60000 usd
CY2024Q1 us-gaap Intangible Assets Current
IntangibleAssetsCurrent
0 usd
CY2024Q3 us-gaap Deferred Costs
DeferredCosts
157045 usd
CY2024Q1 us-gaap Deferred Costs
DeferredCosts
0 usd
CY2024Q3 us-gaap Assets
Assets
1364069 usd
CY2024Q3 us-gaap Notes Payable
NotesPayable
1839731 usd
CY2024Q1 us-gaap Notes Payable
NotesPayable
0 usd
CY2024Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
313669 usd
CY2024Q1 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
0 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
805308 usd
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
825210 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
461989 usd
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
362451 usd
CY2024Q3 us-gaap Loans Payable Current
LoansPayableCurrent
194617 usd
CY2024Q1 us-gaap Loans Payable Current
LoansPayableCurrent
145603 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3615314 usd
CY2024Q3 us-gaap Liabilities
Liabilities
3615314 usd
CY2024Q1 us-gaap Liabilities
Liabilities
1333264 usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 usd
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2000000000 shares
dei Entity Central Index Key
EntityCentralIndexKey
0001442999
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--03-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2025
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2000000000 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1467475449 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1382662949 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
778031952 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
807047948 shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
333-156091
dei Entity Registrant Name
EntityRegistrantName
Alterola Biotech, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-1317032
dei Entity Address Address Line1
EntityAddressAddressLine1
47 Hamilton Square
dei Entity Address City Or Town
EntityAddressCityOrTown
Birkenhead Merseyside
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
CH41 5AR
dei Entity Address Country
EntityAddressCountry
GB
dei City Area Code
CityAreaCode
151
dei Local Phone Number
LocalPhoneNumber
601 9477
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1459502018 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
82720 usd
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2654 usd
CY2024Q3 abti Loans Receivable Current Amount
LoansReceivableCurrentAmount
1063235 usd
CY2024Q1 abti Loans Receivable Current Amount
LoansReceivableCurrentAmount
0 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
1069 usd
CY2024Q1 us-gaap Inventory Net
InventoryNet
1009 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
1147024 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
3663 usd
CY2024Q3 us-gaap Intangible Assets Current
IntangibleAssetsCurrent
60000 usd
CY2024Q1 us-gaap Intangible Assets Current
IntangibleAssetsCurrent
0 usd
CY2024Q3 us-gaap Deferred Costs
DeferredCosts
157045 usd
CY2024Q1 us-gaap Deferred Costs
DeferredCosts
0 usd
CY2024Q3 us-gaap Assets
Assets
1364069 usd
CY2024Q1 us-gaap Assets
Assets
3663 usd
CY2024Q3 us-gaap Notes Payable
NotesPayable
1839731 usd
CY2024Q1 us-gaap Notes Payable
NotesPayable
0 usd
CY2024Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
313669 usd
CY2024Q1 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
0 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
805308 usd
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
825210 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
461989 usd
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
362451 usd
CY2024Q3 us-gaap Loans Payable Current
LoansPayableCurrent
194617 usd
CY2024Q1 us-gaap Loans Payable Current
LoansPayableCurrent
145603 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3615314 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1333264 usd
CY2024Q3 us-gaap Liabilities
Liabilities
3615314 usd
CY2024Q1 us-gaap Liabilities
Liabilities
1333264 usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 usd
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2000000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1467475449 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1382662949 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
1467485 usd
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
1382663 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
10226499 usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
9663951 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-13673734 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-12416075 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
-75214 usd
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
39860 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-2054964 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-1329601 usd
CY2024Q3 us-gaap Minority Interest
MinorityInterest
-196281 usd
CY2024Q1 us-gaap Minority Interest
MinorityInterest
0 usd
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2251245 usd
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1329601 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3663 usd
us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
CY2024Q3 abti Accounting And Audit Fees
AccountingAndAuditFees
91548 usd
CY2023Q3 abti Accounting And Audit Fees
AccountingAndAuditFees
23162 usd
abti Accounting And Audit Fees
AccountingAndAuditFees
213978 usd
abti Accounting And Audit Fees
AccountingAndAuditFees
72100 usd
CY2024Q3 us-gaap Professional Fees
ProfessionalFees
13748 usd
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1467475449 shares
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
1382663 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
10226499 usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
9663951 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-13673734 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-12416075 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
-75214 usd
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
39860 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-2054964 usd
CY2024Q3 us-gaap Minority Interest
MinorityInterest
-196281 usd
CY2024Q1 us-gaap Minority Interest
MinorityInterest
0 usd
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2251245 usd
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1329601 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1364069 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3663 usd
CY2024Q3 us-gaap Revenues
Revenues
0 usd
CY2023Q3 us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
CY2024Q3 abti Accounting And Audit Fees
AccountingAndAuditFees
91548 usd
CY2023Q3 abti Accounting And Audit Fees
AccountingAndAuditFees
23162 usd
abti Accounting And Audit Fees
AccountingAndAuditFees
213978 usd
abti Accounting And Audit Fees
AccountingAndAuditFees
72100 usd
CY2024Q3 us-gaap Professional Fees
ProfessionalFees
13748 usd
CY2023Q3 us-gaap Professional Fees
ProfessionalFees
1895 usd
us-gaap Professional Fees
ProfessionalFees
16049 usd
us-gaap Professional Fees
ProfessionalFees
7185 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16964 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36099 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0 usd
CY2024Q3 us-gaap Legal Fees
LegalFees
96060 usd
CY2023Q3 us-gaap Legal Fees
LegalFees
0 usd
us-gaap Legal Fees
LegalFees
168841 usd
us-gaap Legal Fees
LegalFees
12899 usd
CY2024Q3 us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
0 usd
CY2023Q3 us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
25000 usd
us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
196000 usd
CY2024Q3 abti Consulting Fees
ConsultingFees
234342 usd
CY2023Q3 abti Consulting Fees
ConsultingFees
15937 usd
abti Consulting Fees
ConsultingFees
613400 usd
abti Consulting Fees
ConsultingFees
333678 usd
CY2023Q3 us-gaap Salaries And Wages
SalariesAndWages
33519 usd
us-gaap Salaries And Wages
SalariesAndWages
44209 usd
us-gaap Salaries And Wages
SalariesAndWages
69458 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24023 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23644 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
67477 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25404 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
477231 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
123157 usd
us-gaap Operating Expenses
OperatingExpenses
1160053 usd
us-gaap Operating Expenses
OperatingExpenses
716724 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1160053 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-716724 usd
CY2023Q3 us-gaap Professional Fees
ProfessionalFees
1895 usd
us-gaap Professional Fees
ProfessionalFees
16049 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16964 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36099 usd
CY2024Q3 us-gaap Legal Fees
LegalFees
96060 usd
us-gaap Legal Fees
LegalFees
168841 usd
CY2024Q3 us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
0 usd
CY2023Q3 us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
25000 usd
us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
0 usd
us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
196000 usd
CY2024Q3 abti Consulting Fees
ConsultingFees
234342 usd
abti Consulting Fees
ConsultingFees
333678 usd
CY2024Q3 us-gaap Salaries And Wages
SalariesAndWages
546 usd
CY2023Q3 us-gaap Salaries And Wages
SalariesAndWages
33519 usd
us-gaap Salaries And Wages
SalariesAndWages
44209 usd
us-gaap Salaries And Wages
SalariesAndWages
69458 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24023 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23644 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
67477 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25404 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
477231 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
123157 usd
us-gaap Operating Expenses
OperatingExpenses
1160053 usd
us-gaap Operating Expenses
OperatingExpenses
716724 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-477231 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-123157 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1160053 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-716724 usd
CY2024Q3 us-gaap Extinguishment Of Debt Gain Loss Net Of Tax
ExtinguishmentOfDebtGainLossNetOfTax
0 usd
CY2023Q3 us-gaap Extinguishment Of Debt Gain Loss Net Of Tax
ExtinguishmentOfDebtGainLossNetOfTax
0 usd
us-gaap Extinguishment Of Debt Gain Loss Net Of Tax
ExtinguishmentOfDebtGainLossNetOfTax
0 usd
us-gaap Extinguishment Of Debt Gain Loss Net Of Tax
ExtinguishmentOfDebtGainLossNetOfTax
-138163 usd
CY2024Q3 us-gaap Interest Expense
InterestExpense
337297 usd
us-gaap Interest Expense
InterestExpense
0 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
337297 usd
us-gaap Interest Expense
InterestExpense
0 usd
CY2024Q3 us-gaap Foreign Currency Transaction Gain Loss Unrealized Excluding Investment Price Change After Tax
ForeignCurrencyTransactionGainLossUnrealizedExcludingInvestmentPriceChangeAfterTax
15235 usd
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Unrealized Excluding Investment Price Change After Tax
ForeignCurrencyTransactionGainLossUnrealizedExcludingInvestmentPriceChangeAfterTax
0 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized Excluding Investment Price Change After Tax
ForeignCurrencyTransactionGainLossUnrealizedExcludingInvestmentPriceChangeAfterTax
43310 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized Excluding Investment Price Change After Tax
ForeignCurrencyTransactionGainLossUnrealizedExcludingInvestmentPriceChangeAfterTax
0 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-321962 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-293887 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-138163 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-799193 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-123157 usd
us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-1453940 usd
us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-854887 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-799193 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-123157 usd
us-gaap Net Income Loss
NetIncomeLoss
-1453940 usd
CY2024Q3 us-gaap Extinguishment Of Debt Gain Loss Net Of Tax
ExtinguishmentOfDebtGainLossNetOfTax
0 usd
CY2023Q3 us-gaap Extinguishment Of Debt Gain Loss Net Of Tax
ExtinguishmentOfDebtGainLossNetOfTax
0 usd
us-gaap Extinguishment Of Debt Gain Loss Net Of Tax
ExtinguishmentOfDebtGainLossNetOfTax
0 usd
us-gaap Extinguishment Of Debt Gain Loss Net Of Tax
ExtinguishmentOfDebtGainLossNetOfTax
-138163 usd
CY2024Q3 us-gaap Interest Expense
InterestExpense
337297 usd
us-gaap Interest Expense
InterestExpense
0 usd
us-gaap Interest Expense
InterestExpense
0 usd
CY2024Q3 us-gaap Foreign Currency Transaction Gain Loss Unrealized Excluding Investment Price Change After Tax
ForeignCurrencyTransactionGainLossUnrealizedExcludingInvestmentPriceChangeAfterTax
15235 usd
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Unrealized Excluding Investment Price Change After Tax
ForeignCurrencyTransactionGainLossUnrealizedExcludingInvestmentPriceChangeAfterTax
0 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized Excluding Investment Price Change After Tax
ForeignCurrencyTransactionGainLossUnrealizedExcludingInvestmentPriceChangeAfterTax
43310 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized Excluding Investment Price Change After Tax
ForeignCurrencyTransactionGainLossUnrealizedExcludingInvestmentPriceChangeAfterTax
0 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-321962 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-293887 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-799193 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-123157 usd
us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-854887 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-799193 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-123157 usd
us-gaap Net Income Loss
NetIncomeLoss
-1453940 usd
us-gaap Net Income Loss
NetIncomeLoss
-854887 usd
CY2024Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-107362 usd
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-196281 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0 usd
CY2024Q3 abti Income Loss Attributable To Parents
IncomeLossAttributableToParents
-691831 usd
CY2023Q3 abti Income Loss Attributable To Parents
IncomeLossAttributableToParents
-123157 usd
abti Income Loss Attributable To Parents
IncomeLossAttributableToParents
-1257659 usd
abti Income Loss Attributable To Parents
IncomeLossAttributableToParents
-854887 usd
CY2024Q3 abti Income Loss From Continuing Operations Per Basic
IncomeLossFromContinuingOperationsPerBasic
-0.00
CY2023Q3 abti Income Loss From Continuing Operations Per Basic
IncomeLossFromContinuingOperationsPerBasic
-0.00
abti Income Loss From Continuing Operations Per Basic
IncomeLossFromContinuingOperationsPerBasic
-0.00
abti Income Loss From Continuing Operations Per Basic
IncomeLossFromContinuingOperationsPerBasic
-0.00
CY2024Q3 abti Weighted Average Number Of Share Outstanding Basic
WeightedAverageNumberOfShareOutstandingBasic
1467475253 shares
CY2023Q3 abti Weighted Average Number Of Share Outstanding Basic
WeightedAverageNumberOfShareOutstandingBasic
800109341 shares
abti Weighted Average Number Of Share Outstanding Basic
WeightedAverageNumberOfShareOutstandingBasic
1448712132 shares
abti Weighted Average Number Of Share Outstanding Basic
WeightedAverageNumberOfShareOutstandingBasic
801824998 shares
CY2024Q3 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
799193 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
123157 usd
us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
1453940 usd
us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
854887 usd
CY2024Q3 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4190 usd
CY2023Q3 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26214 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4190 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26214 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-149371 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-881101 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
9761144 usd
abti Shares Reclaimed Into Treasury Shares Amount
SharesReclaimedIntoTreasurySharesAmount
0 usd
abti Shares Issued For Acquisition Of Alinova Resources Amount
SharesIssuedForAcquisitionOfAlinovaResourcesAmount
295000 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
305672 usd
abti Shares Issued For Services Directors Amount
SharesIssuedForServicesDirectorsAmount
171000 usd
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
362451 usd
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2000000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
us-gaap Contract With Customer Asset Allowance For Credit Loss Writeoff
ContractWithCustomerAssetAllowanceForCreditLossWriteoff
12000000 usd
CY2023Q4 abti Loss On Exchange Of Shares For Debt
LossOnExchangeOfSharesForDebt
406575 usd
CY2024 abti Translation Amended Amount
TranslationAmendedAmount
67873 usd
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1467475449 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
778031952 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
807047948 shares
CY2024Q3 us-gaap Notes And Loans Payable
NotesAndLoansPayable
2840318 usd
CY2024Q1 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
0 usd
CY2024Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-107362 usd
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-196281 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0 usd
CY2024Q3 abti Income Loss Attributable To Parents
IncomeLossAttributableToParents
-691831 usd
CY2023Q3 abti Income Loss Attributable To Parents
IncomeLossAttributableToParents
-123157 usd
abti Income Loss Attributable To Parents
IncomeLossAttributableToParents
-1257659 usd
abti Income Loss Attributable To Parents
IncomeLossAttributableToParents
-854887 usd
CY2024Q3 abti Income Loss From Continuing Operations Per Basic
IncomeLossFromContinuingOperationsPerBasic
-0.00
CY2023Q3 abti Income Loss From Continuing Operations Per Basic
IncomeLossFromContinuingOperationsPerBasic
-0.00
abti Income Loss From Continuing Operations Per Basic
IncomeLossFromContinuingOperationsPerBasic
-0.00
abti Income Loss From Continuing Operations Per Basic
IncomeLossFromContinuingOperationsPerBasic
-0.00
CY2024Q3 abti Weighted Average Number Of Share Outstanding Basic
WeightedAverageNumberOfShareOutstandingBasic
1467475253 shares
CY2023Q3 abti Weighted Average Number Of Share Outstanding Basic
WeightedAverageNumberOfShareOutstandingBasic
800109341 shares
abti Weighted Average Number Of Share Outstanding Basic
WeightedAverageNumberOfShareOutstandingBasic
1448712132 shares
abti Weighted Average Number Of Share Outstanding Basic
WeightedAverageNumberOfShareOutstandingBasic
801824998 shares
CY2024Q3 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
799193 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
123157 usd
us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
1453940 usd
CY2024Q3 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4190 usd
CY2023Q3 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26214 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4190 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26214 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-803383 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-149371 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1458130 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-881101 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
9761144 usd
abti Shares Reclaimed Into Treasury Shares Amount
SharesReclaimedIntoTreasurySharesAmount
0 usd
abti Shares Issued For Acquisition Of Alinova Resources Amount
SharesIssuedForAcquisitionOfAlinovaResourcesAmount
295000 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
305672 usd
abti Shares Issued For Services Directors Amount
SharesIssuedForServicesDirectorsAmount
171000 usd
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
157339 usd
abti Shares Reclaimed From Asset Acquisition Cancellation Amount
SharesReclaimedFromAssetAcquisitionCancellationAmount
-12000000 usd
abti Additional Shares Reclaimed From Asset Acquisition Cancellation Amount
AdditionalSharesReclaimedFromAssetAcquisitionCancellationAmount
0 usd
abti Foreign Currency Translation Adjustment Amount
ForeignCurrencyTranslationAdjustmentAmount
83794 usd
us-gaap Net Income Loss
NetIncomeLoss
-854887 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2080938 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-1329601 usd
abti Change In Foreign Currency
ChangeInForeignCurrency
-115074 usd
abti Shares Issued For Services Directors Amount
SharesIssuedForServicesDirectorsAmount
74000 usd
abti Shares Issued For Back Wages Amount
SharesIssuedForBackWagesAmount
28935 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
203700 usd
abti Cash Received For Founders Shares Amount
CashReceivedForFoundersSharesAmount
200 usd
abti Warrants Issued With Convertible Notes
WarrantsIssuedWithConvertibleNotes
340535 usd
us-gaap Net Income Loss
NetIncomeLoss
-1453940 usd
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2251245 usd
us-gaap Net Income Loss
NetIncomeLoss
-1453940 usd
us-gaap Net Income Loss
NetIncomeLoss
-854887 usd
abti Stock Issued During Period Issued For Services
StockIssuedDuringPeriodIssuedForServices
306635 usd
abti Stock Issued During Period Issued For Services
StockIssuedDuringPeriodIssuedForServices
321760 usd
abti Stock Issued During Period Value Issued For Services Directors
StockIssuedDuringPeriodValueIssuedForServicesDirectors
0 usd
abti Stock Issued During Period Value Issued For Services Directors
StockIssuedDuringPeriodValueIssuedForServicesDirectors
180000 usd
abti Shares Issued For Warrants During Period
SharesIssuedForWarrantsDuringPeriod
0 usd
abti Shares Issued For Warrants During Period
SharesIssuedForWarrantsDuringPeriod
13500 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
60 usd
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
157339 usd
abti Shares Reclaimed From Asset Acquisition Cancellation Amount
SharesReclaimedFromAssetAcquisitionCancellationAmount
-12000000 usd
abti Additional Shares Reclaimed From Asset Acquisition Cancellation Amount
AdditionalSharesReclaimedFromAssetAcquisitionCancellationAmount
0 usd
abti Foreign Currency Translation Adjustment Amount
ForeignCurrencyTranslationAdjustmentAmount
83794 usd
us-gaap Net Income Loss
NetIncomeLoss
-854887 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2080938 usd
abti Change In Foreign Currency
ChangeInForeignCurrency
-115074 usd
abti Shares Issued For Services Directors Amount
SharesIssuedForServicesDirectorsAmount
74000 usd
abti Shares Issued For Back Wages Amount
SharesIssuedForBackWagesAmount
28935 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
203700 usd
abti Cash Received For Founders Shares Amount
CashReceivedForFoundersSharesAmount
200 usd
abti Warrants Issued With Convertible Notes
WarrantsIssuedWithConvertibleNotes
340535 usd
us-gaap Net Income Loss
NetIncomeLoss
-1453940 usd
us-gaap Net Income Loss
NetIncomeLoss
-854887 usd
abti Stock Issued During Period Issued For Services
StockIssuedDuringPeriodIssuedForServices
306635 usd
abti Stock Issued During Period Issued For Services
StockIssuedDuringPeriodIssuedForServices
321760 usd
abti Stock Issued During Period Value Issued For Services Directors
StockIssuedDuringPeriodValueIssuedForServicesDirectors
0 usd
abti Stock Issued During Period Value Issued For Services Directors
StockIssuedDuringPeriodValueIssuedForServicesDirectors
180000 usd
abti Shares Issued For Warrants During Period
SharesIssuedForWarrantsDuringPeriod
0 usd
abti Shares Issued For Warrants During Period
SharesIssuedForWarrantsDuringPeriod
13500 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
60 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0 usd
abti Increase Decrease In Vat Taxes Receivable
IncreaseDecreaseInVATTaxesReceivable
0 usd
abti Increase Decrease In Vat Taxes Receivable
IncreaseDecreaseInVATTaxesReceivable
37953 usd
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
0 usd
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
2224 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-19902 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
110319 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
99538 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-8494 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1067729 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-197625 usd
abti Increasedecreaseinacquisition Of Alinova
IncreasedecreaseinacquisitionOfAlinova
0 usd
abti Increasedecreaseinacquisition Of Alinova
IncreasedecreaseinacquisitionOfAlinova
35000 usd
us-gaap Increase Decrease In Lease Acquisition Costs
IncreaseDecreaseInLeaseAcquisitionCosts
60000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
35000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
2493935 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 usd
abti Proceeds From Advanc Pursuant To Loans Receivable Issued
ProceedsFromAdvancPursuantToLoansReceivableIssued
1063235 usd
abti Proceeds From Advanc Pursuant To Loans Receivable Issued
ProceedsFromAdvancPursuantToLoansReceivableIssued
0 usd
us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
157045 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
200 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
abti Purchase Of Common Shares For Cash
PurchaseOfCommonSharesForCash
0 usd
abti Purchase Of Common Shares For Cash
PurchaseOfCommonSharesForCash
-44064 usd
abti Stock Issued During Period Value Treasury Stocks Reissued
StockIssuedDuringPeriodValueTreasuryStocksReissued
0 usd
abti Stock Issued During Period Value Treasury Stocks Reissued
StockIssuedDuringPeriodValueTreasuryStocksReissued
170709 usd
us-gaap Increase Decrease In Notes Payable Related Parties
IncreaseDecreaseInNotesPayableRelatedParties
49014 usd
us-gaap Increase Decrease In Notes Payable Related Parties
IncreaseDecreaseInNotesPayableRelatedParties
290303 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1322869 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
75530 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations
195140 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
87307 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2654 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8890 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
82720 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9102 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0 usd
abti Increase Decrease In Vat Taxes Receivable
IncreaseDecreaseInVATTaxesReceivable
0 usd
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
0 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
99538 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-8494 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1067729 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-197625 usd
abti Increasedecreaseinacquisition Of Alinova
IncreasedecreaseinacquisitionOfAlinova
0 usd
abti Increasedecreaseinacquisition Of Alinova
IncreasedecreaseinacquisitionOfAlinova
35000 usd
us-gaap Increase Decrease In Lease Acquisition Costs
IncreaseDecreaseInLeaseAcquisitionCosts
60000 usd
us-gaap Increase Decrease In Lease Acquisition Costs
IncreaseDecreaseInLeaseAcquisitionCosts
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-60000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
35000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
2493935 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 usd
abti Proceeds From Advanc Pursuant To Loans Receivable Issued
ProceedsFromAdvancPursuantToLoansReceivableIssued
1063235 usd
abti Proceeds From Advanc Pursuant To Loans Receivable Issued
ProceedsFromAdvancPursuantToLoansReceivableIssued
0 usd
us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
157045 usd
us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
200 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
abti Purchase Of Common Shares For Cash
PurchaseOfCommonSharesForCash
0 usd
abti Purchase Of Common Shares For Cash
PurchaseOfCommonSharesForCash
-44064 usd
abti Stock Issued During Period Value Treasury Stocks Reissued
StockIssuedDuringPeriodValueTreasuryStocksReissued
0 usd
us-gaap Increase Decrease In Notes Payable Related Parties
IncreaseDecreaseInNotesPayableRelatedParties
49014 usd
us-gaap Increase Decrease In Notes Payable Related Parties
IncreaseDecreaseInNotesPayableRelatedParties
290303 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1322869 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
75530 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations
195140 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations
-87095 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-115074 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
82720 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9102 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
abti Increase In Equity And Debt Discount
IncreaseInEquityAndDebtDiscount
340535 usd
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
17000 shares
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2024Q3 us-gaap Business Acquisition Percentage Of Voting Interests Acquired
BusinessAcquisitionPercentageOfVotingInterestsAcquired
1 pure
CY2024Q3 abti Working Capital
WorkingCapital
2468290 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-13673734 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
abti Increase In Equity And Debt Discount
IncreaseInEquityAndDebtDiscount
340535 usd
abti Increase In Equity And Debt Discount
IncreaseInEquityAndDebtDiscount
0 usd
us-gaap Nature Of Operations
NatureOfOperations
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>NOTE 1 – NATURE OF BUSINESS, LIQUIDITY &amp; GOING CONCERN</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">After formation, the Company was in the business of mineral exploration. On May 3, 2010, the Company sold its mineral exploration business and entered into an Intellectual Property Assignment Agreement (“IP Agreement”) with Soren Nielsen pursuant to which Mr. Nielsen transferred his right, title and interest in all intellectual property relating to certain chewing gum compositions having appetite suppressant activity (the “IP”) to the Company for the issuance of 55,000,000 shares of the Company’s common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Following the acquisition of the IP the Company changed its business direction to pursue the development of chewing gums for the delivery of Nutraceutical/functional ingredients for applications such as appetite suppressant, cholesterol suppressant, vitamin delivery, antioxidant delivery and motion sickness suppressant.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On January 19, 2021, the Company entered into a Stock Purchase Agreement (the “Agreement”) with ABTI Pharma Limited, a company registered in England and Wales (“ABTI Pharma”), pursuant to which the Company agreed to acquire all of the outstanding shares of capital stock of ABTI Pharma from its shareholders in exchange for 600,000,000 shares of the Company pro rata to the ABTI Pharma shareholders. The shares were issued on January 29, 2021 in anticipation of the closing and the parties to the transaction agreed in a March 24, 2021 amendment to close upon the ABTI Pharma Limited Shares being transferred to the Company, which was to occur upon the filing by the Company of its outstanding September 30, 2020 quarterly report on Form 10-Q, which was filed on May 28, 2021 with the Securities and Exchange Commission. The transaction closed on May 28, 2021.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The transaction was accounted for as a reverse acquisition and recapitalization. ABTI Pharma is the acquirer for accounting purposes and the Company is the issuer. The historical financial statements presented are the financial statements of ABTI. The Agreement was treated as a recapitalization and not as a business combination; at the date of the acquisition, the net liabilities of the legal acquirer, Alterola, were $389,721.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The business plan of the Company is no longer focused on a chewing gum delivery system but was re-focused on the development of cannabinoid, cannabinoid-like, and non-cannabinoid pharmaceutical active pharmaceutical ingredients (APIs), pharmaceutical medicines made from cannabinoid, cannabinoid-like, and non-cannabinoid APIs and European novel food approval of cannabinoid-based, cannabinoid-like and non-cannabinoid ingredients and products. In addition, the company plans to develop such bulk ingredients for supply into the cosmetic sector.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On December 2, 2021, the Company closed an Asset Purchase Agreement (the “Purchase Agreement”) with C2 Wellness Corp., a Wyoming corporation, and Dr. G. Sridhar Prasad (together, the “Seller”) and acquired certain IP assets (the “Assets”) from Seller, which include:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Novel cannabinoid molecules and their associated intellectual property;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Novel cannabinoid pro-drugs, and their associated intellectual property;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Novel proprietary cannabinoid formulations, designed to target lymphatic delivery, and their associated intellectual property;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Novel proprietary nano-encapsulated cannabinoid formulations, in self-dissolving polymers, and their associated intellectual property; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cannabinoids and cannabinoid pro-drug formulations for topical ocular delivery, and their associated intellectual property.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">  </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In exchange for the Assets, the Company issued to Seller shares of common stock. On September 8, 2023, the Company and Seller entered into an Agreement to sell the assets, such that the Company sold the assets back to the Seller and the Seller paid 29,015,993 shares of ABTI common stock to the Company. The assets were sold to the Seller in September 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As of April 18, 2023, the Company acquired intellectual property from Alinova Biosciences Ltd. The Company acquired Alinova’s joint interest in the patent family of PTX 0001. The Company paid 35,000 Sterling in cash and 5,000,000 shares of ABTI Stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On April 16, 2024, the Company formed a new subsidiary Phytanix Bio, with 1,000 Common shares and 17,000 Preferred Shares originally being authorized as founding shares. On May 16, 2024, Phytanix Bio amended its articles of incorporation to change the amount of authorized shares capital of Phytanix Bio to 10,000,000 common shares and 100,000 preferred shares. Additionally, the Company authorized the acquisition of 100% of the share capital of ABTI Pharma Ltd and subsidiaries by Phytanix Bio for the consideration of 5,000,000 Phytanix Bio shares. Phytanix Bio was formed to become the parent of ABTI Pharma Limited and its subsidiaries. Phytanix Bio was formed to execute a merger transaction with NASDAQ-listed company Chain Bridge I (NASDAQ: CBRG), which as of the date of this filing has not yet closed.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>LIQUIDITY &amp; GOING CONCERN</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On September 30, 2024, the Company has negative working capital of $2,468,290 has incurred losses since inception of $13,673,734, and has not received revenues from sales of products or services. These factors create substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustment that might be necessary if the Company is unable to continue as a going concern.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The ability of Alterola to continue as a going concern is dependent on the Company generating cash from the sale of its common stock and/or obtaining debt financing and attaining future profitable operations. Management’s plans include selling its equity securities and obtaining debt financing to fund its capital requirement and ongoing operations; however, there can be no assurance the Company will be successful in these efforts.</p>
CY2021Q2 us-gaap Liabilities
Liabilities
389721 usd
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000 shares
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
17000 shares
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000 shares
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2024Q3 us-gaap Business Acquisition Percentage Of Voting Interests Acquired
BusinessAcquisitionPercentageOfVotingInterestsAcquired
1 pure
CY2024Q3 abti Working Capital
WorkingCapital
2468290 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-13673734 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
392278 usd
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
392278 usd
CY2023Q1 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
189355 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
805308 usd
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
825210 usd
CY2023Q1 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
189355 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
805308 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
461989 usd
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
362451 usd
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2000000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
461989 usd
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
362451 usd
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2000000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 abti Loss On Exchange Of Shares For Debt
LossOnExchangeOfSharesForDebt
406575 usd
CY2024 abti Translation Amended Amount
TranslationAmendedAmount
67873 usd
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1467475449 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1382662949 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
778031952 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
807047948 shares
CY2024Q3 us-gaap Notes And Loans Payable
NotesAndLoansPayable
2840318 usd
CY2024Q1 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
0 usd
CY2024Q3 us-gaap Other Notes Payable Current
OtherNotesPayableCurrent
2840318 usd
CY2024Q1 us-gaap Other Notes Payable Current
OtherNotesPayableCurrent
0 usd
CY2024Q3 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
-1000587 usd
CY2024Q1 us-gaap Notes And Loans Payable
NotesAndLoansPayable
0 usd
CY2024Q3 us-gaap Notes Receivable Net
NotesReceivableNet
1839731 usd
CY2024Q1 us-gaap Notes Receivable Net
NotesReceivableNet
0 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
333529 usd
CY2024Q3 us-gaap Investment Interest Rate
InvestmentInterestRate
0.12 pure
CY2024Q3 abti Convertible Note Payable Description
ConvertibleNotePayableDescription
The initial note was for $310,000 and was convertible for up to 90% of the price of the note outstanding
CY2024Q3 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
310000 usd
CY2024Q3 us-gaap Investment Owned Balance Principal Amount
InvestmentOwnedBalancePrincipalAmount
313669 usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
us-gaap Contract With Customer Asset Allowance For Credit Loss Writeoff
ContractWithCustomerAssetAllowanceForCreditLossWriteoff
12000000 usd
CY2023Q4 abti Loss On Exchange Of Shares For Debt
LossOnExchangeOfSharesForDebt
406575 usd
CY2024 abti Translation Amended Amount
TranslationAmendedAmount
67873 usd
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1467475449 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1382662949 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
778031952 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
807047948 shares
CY2024Q3 us-gaap Notes And Loans Payable
NotesAndLoansPayable
2840318 usd
CY2024Q1 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
0 usd
CY2024Q3 us-gaap Other Notes Payable Current
OtherNotesPayableCurrent
2840318 usd
CY2024Q1 us-gaap Other Notes Payable Current
OtherNotesPayableCurrent
0 usd
CY2024Q3 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
-1000587 usd
CY2024Q1 us-gaap Notes And Loans Payable
NotesAndLoansPayable
0 usd
CY2024Q3 us-gaap Notes Receivable Net
NotesReceivableNet
1839731 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
333529 usd
CY2024Q3 us-gaap Investment Interest Rate
InvestmentInterestRate
0.12 pure
CY2024Q3 abti Convertible Note Payable Description
ConvertibleNotePayableDescription
The initial note was for $310,000 and was convertible for up to 90% of the price of the note outstanding
CY2024Q3 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
310000 usd
CY2024Q3 us-gaap Investment Owned Balance Principal Amount
InvestmentOwnedBalancePrincipalAmount
313669 usd
abti Shareholder Advances
ShareholderAdvances
49014 usd
CY2024Q3 abti Notes Payable Related Parties Classified Current Amount
NotesPayableRelatedPartiesClassifiedCurrentAmount
1839731 usd
CY2024Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
313669 usd
CY2024Q3 us-gaap Other Notes Payable Current
OtherNotesPayableCurrent
2840318 usd
CY2024Q1 us-gaap Other Notes Payable Current
OtherNotesPayableCurrent
0 usd
CY2024Q3 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
-1000587 usd
CY2024Q3 us-gaap Notes Receivable Net
NotesReceivableNet
1839731 usd
CY2024Q3 us-gaap Investment Interest Rate
InvestmentInterestRate
0.12 pure
CY2024Q3 abti Convertible Note Payable Description
ConvertibleNotePayableDescription
The initial note was for $310,000 and was convertible for up to 90% of the price of the note outstanding
CY2024Q3 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
310000 usd
CY2024Q3 us-gaap Investment Owned Balance Principal Amount
InvestmentOwnedBalancePrincipalAmount
313669 usd
abti Shareholder Advances
ShareholderAdvances
49014 usd
CY2024Q3 abti Notes Payable Related Parties Classified Current Amount
NotesPayableRelatedPartiesClassifiedCurrentAmount
1839731 usd
CY2024Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
313669 usd
abti Shareholder Advances
ShareholderAdvances
49014 usd
CY2024Q3 abti Notes Payable Related Parties Classified Current Amount
NotesPayableRelatedPartiesClassifiedCurrentAmount
1839731 usd
CY2024Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
313669 usd

Files In Submission

Name View Source Status
0001477932-24-007731-index-headers.html Edgar Link pending
0001477932-24-007731-index.html Edgar Link pending
0001477932-24-007731.txt Edgar Link pending
0001477932-24-007731-xbrl.zip Edgar Link pending
abti-20240930.xsd Edgar Link pending
abti_10q.htm Edgar Link pending
abti_10qimg2.jpg Edgar Link pending
abti_ex311.htm Edgar Link pending
abti_ex312.htm Edgar Link pending
abti_ex321.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
abti-20240930_cal.xml Edgar Link unprocessable
abti-20240930_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
abti_10q_htm.xml Edgar Link completed
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
abti-20240930_lab.xml Edgar Link unprocessable
abti-20240930_pre.xml Edgar Link unprocessable